Dr Aris Angelis
BSc MSc MSc PhD
15-17 Tavistock Place
Dr Aris Angelis is an Assistant Professor in Health Economics with the Department of Health Services Research and Policy at the London School of Hygiene and Tropical Medicine (LSHTM). Before joining LSHTM, Aris was at the London School of Economics and Political Science (LSE), working as a Research Fellow at LSE Health and a Guest Teacher at the Department of Health Policy, where he is now a Visiting Fellow. He was a 2021-2022 NICE Scholar.
Aris received his Doctor of Philosophy (PhD) in Pharmaceutical Policy and Economics from the Department of Social Policy at LSE. His PhD investigated the development and application of a methodological framework based on Multiple Criteria Decision Analysis (MCDA) for assessing the value of new medical technologies in the context of HTA, to inform resource allocation decisions and incentivise socially desirable R&D investments. He also holds an MSc in International Health Policy from the LSE, an MSc in Biopharmacy from King’s College London and a BSc in Biochemistry from Imperial College London.
Aris is teaching in the Introduction to Health Economics and Economic Evaluation modules.
Aris’ main interests are in Health Technology Assessment (HTA) with a focus on multi-disciplinary methodological and applied health services research for health care evaluation using health economics and decision analysis.
Aris has been awarded a National Institute for Health and Care Excellence (NICE) Scholarship, a one-year opportunity to work part-time on a NICE-supported project, becoming the first health economist admitted to the programme. The topic of the project was on the appraisal of the Cancer Drugs Fund with the goal of advancing value assessment methods for new cancer drugs.
While at LSE, Aris had been involved with the EU funded project IMPACT-HTA, co-leading the research activities of a work package on multi-criteria value methods and working towards a new value framework for medicines in collaboration with different HTA bodies. He is also involved in a project initiative with the European Society for Medical Oncology (ESMO), co-leading research activities towards the development of an ESMO value framework for cancer medicines. In the past, Aris has undertaken contracted research, training and advisory work for the Department of Health and Social Care, the European Commission, the World Health Organization, national health ministries and various biopharmaceutical organisations.
Google Scholar page: https://scholar.google.co.uk/citations?user=YEcogaQAAAAJ&hl=en